Lagerwall, CathrineShahin, HadyAbdallah, SallamSteinvall, IngridElmasry, MoustafaSjoberg, FolkeEl-Serafi, Ahmed T2021-10-032021-10-032021-12https://doi.org/10.1016/j.reth.2021.09.005https://qrgo.page.link/zKjQAIntroduction: Regenerative solutions of the skin represent a hope for burn victims with extensive skin loss and chronic wound patients. The development of xeno-free workflow is crucial for clinical appli- cation in compliance with the directives of the European Medicines Agency. This study aimed at eval- uating the outcome of the xeno-free isolation workflow of keratinocytes from human skin biopsy. Methods: Skin biopsies were obtained from volunteers. The epidermis was digested with TrypLE™ Select, which was deactivated by dilution or with trypsin, deactivated by media with fetal bovine serum. Freshly isolated cells were compared for total cell number, viability, activity of caspase 3, gene expression and the presence of the keratinocyte surface markers cytokeratin 14. The cells were cultured in xeno-free conditions for one week and characterized regarding the number and viability as well as the metal- loproteinase secretion. Results: The number of obtained cells was similar in both workflows. The cell viability was less in the TrypLE group, with slight reduction of the cell surface marker cytokeratin 14. Caspase 3 activity was comparable as well as the gene expression of the apoptotic markers BAX, BCL2 and SLUG, as well as the keratinocyte markers cytokeratin 14, stratifin and filaggrin. Upon culture, the number of keratinocytes, their viability and secretion of matrix metalloproteinases 1 and 10 were equal in both groups. Conclusion: This study reports the possibility of isolating functioning and viable keratinocytes through a xeno-free workflow for clinical application. © 2021, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).en-USKeratinocytesRegenerative medicineEuropean medicines agencyXeno-freeTrypLETrypsinArticlehttps://doi.org/10.1016/j.reth.2021.09.005